The investigation of LDHA in the immune microenvironment and its potential impact on the efficacy of immunotherapeutic interventions will offer new perspectives on the treatment of NAFLD-related LC progressing to HCC. Here, LDHA is linked to metabolic dysfunction-associated steatotic liver disease.